Timothy J Bernard1, Michael J Rivkin1, Kelley Scholz1, Gabrielle deVeber1, Adam Kirton1, Joan Cox Gill1, Anthony K Chan1, Collin A Hovinga1, Rebecca N Ichord1, James C Grotta1, Lori C Jordan1, Susan Benedict1, Neil R Friedman1, Michael M Dowling1, Jorina Elbers1, Marcela Torres1, Sally Sultan1, Dana D Cummings1, Eric F Grabowski1, Hugh J McMillan1, Lauren A Beslow1, Catherine Amlie-Lefond2. 1. From the Department of Neurology, Children's Hospital Colorado, Aurora (T.J.B.); Departments of Neurology, Psychiatry and Radiology, Boston Children's Hospital, MA (M.J.R.); Department of Neurology, Hospital for Sick Children, Toronto, Ontario, Canada (G.d.V.), Department of Neurology, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada (A.K.); Department of Pediatrics, Medical College of Wisconsin, Milwaukee, and BloodCenter of Wisconsin (J.C.G.); Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada (A.K.C.); Department of Pediatrics, Dell Children's Medical Center, Austin, TX (C.A.H.), Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia (R.N.I.); Department of Neurology, Memorial Hermann Hospital, Houston, TX (J.C.G.); Division of Pediatric Neurology, Vanderbilt University, Nashville, TN (L.C.J.); Department of Neurology, Primary Children's Medical Center, Salt Lake City, UT (S.B.); Department of Neurology, Cleveland Clinic, OH (N.R.F.); Department of Pediatrics and Neurology, UT Southwestern Medical Center, Dallas TX (M.M.D.); Department of Neurology, Stanford University, CA (J.E.); Department of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX (M.T.); Department of Neurology, Columbia University Medical Center, New York, NY (S.S.); Division of Child Neurology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, PA (D.D.C.); Division of Pediatric Hematology/Oncology, Department of Pediatrics, Mass General Hospital for Children, and Massachusetts General Hospital, Boston (E.F.G.); Department of Neurology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada (H.J.M.); Departments of Pediatrics and Neurology, Yale-New Haven Children's Hospital, CT (L.A.B.); Department of Neurology, Seattle Children's Hospital, WA (K.S., C.A.-L.); and Department of Neurology, University of Washington, Seattle (C.A.-L.). 2. From the Department of Neurology, Children's Hospital Colorado, Aurora (T.J.B.); Departments of Neurology, Psychiatry and Radiology, Boston Children's Hospital, MA (M.J.R.); Department of Neurology, Hospital for Sick Children, Toronto, Ontario, Canada (G.d.V.), Department of Neurology, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada (A.K.); Department of Pediatrics, Medical College of Wisconsin, Milwaukee, and BloodCenter of Wisconsin (J.C.G.); Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada (A.K.C.); Department of Pediatrics, Dell Children's Medical Center, Austin, TX (C.A.H.), Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia (R.N.I.); Department of Neurology, Memorial Hermann Hospital, Houston, TX (J.C.G.); Division of Pediatric Neurology, Vanderbilt University, Nashville, TN (L.C.J.); Department of Neurology, Primary Children's Medical Center, Salt Lake City, UT (S.B.); Department of Neurology, Cleveland Clinic, OH (N.R.F.); Department of Pediatrics and Neurology, UT Southwestern Medical Center, Dallas TX (M.M.D.); Department of Neurology, Stanford University, CA (J.E.); Department of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX (M.T.); Department of Neurology, Columbia University Medical Center, New York, NY (S.S.); Division of Child Neurology, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, PA (D.D.C.); Division of Pediatric Hematology/Oncology, Department of Pediatrics, Mass General Hospital for Children, and Massachusetts General Hospital, Boston (E.F.G.); Department of Neurology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada (H.J.M.); Departments of Pediatrics and Neurology, Yale-New Haven Children's Hospital, CT (L.A.B.); Department of Neurology, Seattle Children's Hospital, WA (K.S., C.A.-L.); and Department of Neurology, University of Washington, Seattle (C.A.-L.). Calefond@uw.ed
Abstract
BACKGROUND AND PURPOSE: In adult stroke, the advent of thrombolytic therapy led to the development of primary stroke centers capable to diagnose and treat patients with acute stroke rapidly. We describe the development of primary pediatric stroke centers through preparation of participating centers in the Thrombolysis in Pediatric Stroke (TIPS) trial. METHODS: We collected data from the 17 enrolling TIPS centers regarding the process of becoming an acute pediatric stroke center with capability to diagnose, evaluate, and treat pediatric stroke rapidly, including use of thrombolytic therapy. RESULTS: Before 2004, <25% of TIPS sites had continuous 24-hour availability of acute stroke teams, MRI capability, or stroke order sets, despite significant pediatric stroke expertise. After TIPS preparation, >80% of sites now have these systems in place, and all sites reported increased readiness to treat a child with acute stroke. Use of a 1- to 10-Likert scale on which 10 represented complete readiness, median center readiness increased from 6.2 before site preparation to 8.7 at the time of site activation (P≤0.001). CONCLUSIONS: Before preparing for TIPS, centers interested in pediatric stroke had not developed systematic strategies to diagnose and treat acute pediatric stroke. TIPS trial preparation has resulted in establishment of pediatric acute stroke centers with clinical and system preparedness for evaluation and care of children with acute stroke, including use of a standardized protocol for evaluation and treatment of acute arterial stroke in children that includes use of intravenous tissue-type plasminogen activator. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01591096.
BACKGROUND AND PURPOSE: In adult stroke, the advent of thrombolytic therapy led to the development of primary stroke centers capable to diagnose and treat patients with acute stroke rapidly. We describe the development of primary pediatric stroke centers through preparation of participating centers in the Thrombolysis in Pediatric Stroke (TIPS) trial. METHODS: We collected data from the 17 enrolling TIPS centers regarding the process of becoming an acute pediatric stroke center with capability to diagnose, evaluate, and treat pediatric stroke rapidly, including use of thrombolytic therapy. RESULTS: Before 2004, <25% of TIPS sites had continuous 24-hour availability of acute stroke teams, MRI capability, or stroke order sets, despite significant pediatric stroke expertise. After TIPS preparation, >80% of sites now have these systems in place, and all sites reported increased readiness to treat a child with acute stroke. Use of a 1- to 10-Likert scale on which 10 represented complete readiness, median center readiness increased from 6.2 before site preparation to 8.7 at the time of site activation (P≤0.001). CONCLUSIONS: Before preparing for TIPS, centers interested in pediatric stroke had not developed systematic strategies to diagnose and treat acute pediatric stroke. TIPS trial preparation has resulted in establishment of pediatric acute stroke centers with clinical and system preparedness for evaluation and care of children with acute stroke, including use of a standardized protocol for evaluation and treatment of acute arterial stroke in children that includes use of intravenous tissue-type plasminogen activator. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01591096.
Authors: Lauren A Beslow; Scott E Kasner; Sabrina E Smith; Michael T Mullen; Matthew P Kirschen; Rachel A Bastian; Michael M Dowling; Warren Lo; Lori C Jordan; Timothy J Bernard; Neil Friedman; Gabrielle DeVeber; Adam Kirton; Lisa Abraham; Daniel J Licht; Abbas F Jawad; Jonas H Ellenberg; Ebbing Lautenbach; Rebecca N Ichord Journal: Stroke Date: 2011-11-10 Impact factor: 7.914
Authors: Mubeen F Rafay; Ann-Marie Pontigon; Jackie Chiang; Margaret Adams; D Anna Jarvis; Frank Silver; Daune Macgregor; Gabrielle A Deveber Journal: Stroke Date: 2008-09-18 Impact factor: 7.914
Authors: Rebecca N Ichord; Rachel Bastian; Lisa Abraham; Rand Askalan; Susan Benedict; Timothy J Bernard; Lauren Beslow; Gabrielle Deveber; Michael Dowling; Neil Friedman; Heather Fullerton; Lori Jordan; Li Kan; Adam Kirton; Catherine Amlie-Lefond; Daniel Licht; Warren Lo; Chalmer McClure; Steve Pavlakis; Sabrina E Smith; Marilyn Tan; Scott Kasner; Abbas F Jawad Journal: Stroke Date: 2011-02-11 Impact factor: 7.914
Authors: Dana Leifer; Dawn M Bravata; J J Buddy Connors; Judith A Hinchey; Edward C Jauch; S Claiborne Johnston; Richard Latchaw; William Likosky; Christopher Ogilvy; Adnan I Qureshi; Debbie Summers; Gene Y Sung; Linda S Williams; Richard Zorowitz Journal: Stroke Date: 2011-01-13 Impact factor: 7.914
Authors: Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks Journal: Stroke Date: 2007-04-12 Impact factor: 7.914
Authors: E Steve Roach; Meredith R Golomb; Robert Adams; Jose Biller; Stephen Daniels; Gabrielle Deveber; Donna Ferriero; Blaise V Jones; Fenella J Kirkham; R Michael Scott; Edward R Smith Journal: Stroke Date: 2008-07-17 Impact factor: 7.914
Authors: Cydni N Williams; Mary E Hartman; Kristin P Guilliams; Rejean M Guerriero; Juan A Piantino; Christopher C Bosworth; Skyler S Leonard; Kathryn Bradbury; Amanda Wagner; Trevor A Hall Journal: Curr Treat Options Neurol Date: 2019-09-27 Impact factor: 3.598
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Adriane J Sinclair; Christine K Fox; Rebecca N Ichord; Christopher S Almond; Timothy J Bernard; Lauren A Beslow; Anthony K C Chan; Michael Cheung; Gabrielle deVeber; Michael M Dowling; Neil Friedman; Therese M Giglia; Kristin P Guilliams; Tilman Humpl; Daniel J Licht; Mark T Mackay; Lori C Jordan Journal: Pediatr Neurol Date: 2014-10-05 Impact factor: 3.372
Authors: Thomas P Madaelil; Akash P Kansagra; DeWitte T Cross; Christopher J Moran; Colin P Derdeyn Journal: Interv Neuroradiol Date: 2016-03-04 Impact factor: 1.610